谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

1437P Tislelizumab (TIS) + Chemotherapy (CT) Vs Placebo (PBO) + CT in HER2-negative Advanced or Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (GC/GEJC): RATIONALE-305 Study Minimum 3-Year Survival Follow-Up

M. Cruz-Correa,D-Y. Oh, K. Kato,J. Tabernero,Y. Bai,J. Shi,K-W. Lee, H. Hirano, D.R. Spigel,L.S. Wyrwicz,R.A. Pazo Cid,A. Cubillo Gracian, L. Li, Y. Xu,T. Sheng, S. Yang,R-H. Xu,M. Moehler

Annals of Oncology（2024）

引用 0|浏览2
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要